Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce it has signed its first material contract with an American sleep medicine group which will adopt the Company’s O2Vent® treatment platform for the treatment of obstructive sleep apnoea (OSA) across 8 clinical treatment sites. The agreement identifies Oventus as the primary supplier for oral appliances for the treatment of OSA.
For more information, download the attached PDF.
Download this document
